Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9719832 | 0.90 | F2 (0.58) | PPARAKDM4EMEN1KMT2AMAOB | |
| SCHEMBL28807452 | 0.79 | TLR4 (0.49) | KDM4EMEN1KMT2ASMN1; SMN2MAOB | |
| SCHEMBL3230228 | 0.78 | SMN1; SMN2 (0.62) | MEN1KMT2ASMN1; SMN2MAOBHTT | |
| SCHEMBL9719835 | 0.76 | APP (0.55) | KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17712563 | 0.75 | SMN1; SMN2 (0.63) | KDM4ESMN1; SMN2HTTALDH1A1TP53 | |
| SCHEMBL9719798 | 0.75 | CYP1A2 (0.53) | MEN1KMT2ASMN1; SMN2F2ALDH1A1 | |
| SCHEMBL9719801 | 0.75 | F2 (0.63) | KDM4EMEN1KMT2ASMN1; SMN2MAOB | |
| SCHEMBL1964976 | 0.74 | BCHE (0.63) | PPARAKDM4EMEN1KMT2AHTT | |
| SCHEMBL5310163 | 0.74 | MEN1 (0.68) | PPARAKDM4EMEN1KMT2AMAOB | |
| SCHEMBL9719852 | 0.74 | ALDH1A1 (0.48) | KDM4EMEN1KMT2ASMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | disclosed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023446-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | PPARA 4241/4885KDM4E 599/4885MEN1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.